Tali Azenkot, MD, discusses the rationale for combining dupilumab with cemiplimab in early-stage, resectable non–small cell lung cancer.
Tali Azenkot, MD
Advertisement
Tali Azenkot, MD, is a fellow of hematology and oncology at the University of California San Diego Health.
Articles by Tali Azenkot, MD
Advertisement
Latest Updated Articles
Dr Azenkot on Dupilumab Plus Cemiplimab in Early-Stage, Resectable NSCLCPublished: July 7th 2025 | Updated:
Advertisement
Advertisement
Trending on OncLive
1
FDA Grants Priority Review to Gedatolisib for HR+, HER2-Negative Advanced Breast Cancer
2
NCCN Guidelines Recognize MammaPrint/BluePrint for Determining Anthracycline Benefit in Breast Cancer
3
Nogapendekin Alfa Inbakicept Plus NK Cell Therapy Yields Strong OS Signal in Recurrent Glioblastoma
4
Unpacking the FDA Approvals That Reshaped Cancer Care in 2025
5